European Commission Approves Combination Therapy Involving Pfizer and Astellas

The European Commission has approved a combination therapy involving Pfizer and Astellas, consisting of pembrolizumab and enfortumab vedotin. This decision is based on the Phase 3 Keynote-B15 study, which showed a 47% reduction in the risk of event-free survival (EFS) events, including disease progression, recurrence, or death. This approval represents a significant milestone for the collaboration between the two companies.